[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"@StonkChris Consider #biotechs also way below historical highs . $ntla $pali $nktr $bioa $sdgr $crsp $prme $crnx $bhvn . just to name some"
X Link @LTbioinvestor 2025-10-08T13:01Z 17.1K followers, XXX engagements
"👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼 $BIOA $ESAIY $ESALF $BIIB @bioarcticab @eisaiusneuro @biogen #Bioarctic #AlzheimersDisease #Leqembi #lecanemab #ParkinsonsDisease #exidavnemab #ALS"
X Link @larsen210 2025-10-08T06:27Z XXX followers, XX engagements
"💼 $GOOGL Google $AMPX Amprius Technologies $NTLA Intellia Therapeutics $MDXH MDxHealth $AIRO Airo Group $OSSD OssDsign $SGMO Sangamo Therapeutics $SRPT Sarepta Therapeutics $NKTR Nektar Therapeutics $MCLAIR Medclair $NOVO Novo Nordisk $BIOA BioArctic"
X Link @Drbagholders 2025-10-07T17:22Z XXX followers, 1290 engagements
"$BIOA $ESAIY Leqembi Iqlik (lecanemab-irmb) maintenance treatment launched in the United States BioArctic partner Eisai launched Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector in the U.S. on October X 2025 as a maintenance option for early Alzheimers disease (MCI or mild dementia) after an initial 18-month IV induction. After XX months of XX mg/kg IV every two weeks patients may continue IV every four weeks or switch to a weekly XXX mg at-home subcutaneous injection. The company also launched a Leqembi Companion program with nurse education financial/insurance support an injection"
X Link @MarcJacksonLA 2025-10-06T22:49Z 7555 followers, XXX engagements